PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease (vol 14, 1326078, 2024)

Lorenz Kocheise; Ignazio Piseddu; Joscha Vonderlin; Eric T. Tjwa; Gustav Buescher; Lucy Meunier; Pia Goeggelmann; Francesca Fianchi; Jerome Dumortier; Mar Riveiro Barciela; Tom J. G. Gevers; Benedetta Terziroli Beretta-Piccoli; Maria-Carlota Londono; Sona Frankova; Thomas Roesner; Vincent Joerg; Constantin Schmidt; Fabian Glaser; Jan P. Sutter; Thorben W. Fruendt; Ansgar W. Lohse; Samuel Huber; Johann von Felden; Marcial Sebode; Kornelius Schulze

doi:10.3389/fimmu.2024.1369747

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease (vol 14, 1326078, 2024)

Lorenz Kocheise^*, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jerome Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londono, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. FruendtAnsgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Original language	English
Article number	1369747
Number of pages	2
Journal	Frontiers in Immunology
Volume	15
DOIs	https://doi.org/10.3389/fimmu.2024.1369747
Publication status	Published - 24 Jan 2024

Keywords

autoimmune disease (AID)
immune checkpoint inhibitors (ICI)
autoimmune liver diseases (AILD)
immune related adverse effects (irAEs)
PD-1/PD-L1 immune checkpoint inhibitors
autoimmune hepatitis (AIH)
primary sclerosing cholangites (PSC)
primary biliary cholangitis (PBC)

Access to Document

10.3389/fimmu.2024.1369747Licence: CC BY

Cite this

Kocheise, L., Piseddu, I., Vonderlin, J., Tjwa, E. T., Buescher, G., Meunier, L., Goeggelmann, P., Fianchi, F., Dumortier, J., Barciela, M. R., Gevers, T. J. G., Beretta-Piccoli, B. T., Londono, M.-C., Frankova, S., Roesner, T., Joerg, V., Schmidt, C., Glaser, F., Sutter, J. P., ... Schulze, K. (2024). PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease (vol 14, 1326078, 2024). Frontiers in Immunology, 15, Article 1369747. https://doi.org/10.3389/fimmu.2024.1369747

@article{b16e094e0ed846eea3f6b2beff297e21,

title = "PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease (vol 14, 1326078, 2024)",

keywords = "autoimmune disease (AID), immune checkpoint inhibitors (ICI), autoimmune liver diseases (AILD), immune related adverse effects (irAEs), PD-1/PD-L1 immune checkpoint inhibitors, autoimmune hepatitis (AIH), primary sclerosing cholangites (PSC), primary biliary cholangitis (PBC)",

author = "Lorenz Kocheise and Ignazio Piseddu and Joscha Vonderlin and Tjwa, {Eric T.} and Gustav Buescher and Lucy Meunier and Pia Goeggelmann and Francesca Fianchi and Jerome Dumortier and Barciela, {Mar Riveiro} and Gevers, {Tom J. G.} and Beretta-Piccoli, {Benedetta Terziroli} and Maria-Carlota Londono and Sona Frankova and Thomas Roesner and Vincent Joerg and Constantin Schmidt and Fabian Glaser and Sutter, {Jan P.} and Fruendt, {Thorben W.} and Lohse, {Ansgar W.} and Samuel Huber and {von Felden}, Johann and Marcial Sebode and Kornelius Schulze",

year = "2024",

month = jan,

day = "24",

doi = "10.3389/fimmu.2024.1369747",

language = "English",

volume = "15",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media S.A.",

}

Kocheise, L, Piseddu, I, Vonderlin, J, Tjwa, ET, Buescher, G, Meunier, L, Goeggelmann, P, Fianchi, F, Dumortier, J, Barciela, MR, Gevers, TJG, Beretta-Piccoli, BT, Londono, M-C, Frankova, S, Roesner, T, Joerg, V, Schmidt, C, Glaser, F, Sutter, JP, Fruendt, TW, Lohse, AW, Huber, S, von Felden, J, Sebode, M & Schulze, K 2024, 'PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease (vol 14, 1326078, 2024)', Frontiers in Immunology, vol. 15, 1369747. https://doi.org/10.3389/fimmu.2024.1369747

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease (vol 14, 1326078, 2024). / Kocheise, Lorenz; Piseddu, Ignazio; Vonderlin, Joscha et al.
In: Frontiers in Immunology, Vol. 15, 1369747, 24.01.2024.

Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

TY - JOUR

T1 - PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease (vol 14, 1326078, 2024)

AU - Kocheise, Lorenz

AU - Piseddu, Ignazio

AU - Vonderlin, Joscha

AU - Tjwa, Eric T.

AU - Buescher, Gustav

AU - Meunier, Lucy

AU - Goeggelmann, Pia

AU - Fianchi, Francesca

AU - Dumortier, Jerome

AU - Barciela, Mar Riveiro

AU - Gevers, Tom J. G.

AU - Beretta-Piccoli, Benedetta Terziroli

AU - Londono, Maria-Carlota

AU - Frankova, Sona

AU - Roesner, Thomas

AU - Joerg, Vincent

AU - Schmidt, Constantin

AU - Glaser, Fabian

AU - Sutter, Jan P.

AU - Fruendt, Thorben W.

AU - Lohse, Ansgar W.

AU - Huber, Samuel

AU - von Felden, Johann

AU - Sebode, Marcial

AU - Schulze, Kornelius

PY - 2024/1/24

Y1 - 2024/1/24

KW - autoimmune disease (AID)

KW - immune checkpoint inhibitors (ICI)

KW - autoimmune liver diseases (AILD)

KW - immune related adverse effects (irAEs)

KW - PD-1/PD-L1 immune checkpoint inhibitors

KW - autoimmune hepatitis (AIH)

KW - primary sclerosing cholangites (PSC)

KW - primary biliary cholangitis (PBC)

U2 - 10.3389/fimmu.2024.1369747

DO - 10.3389/fimmu.2024.1369747

M3 - Erratum / corrigendum / retractions

SN - 1664-3224

VL - 15

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 1369747

ER -